Page 2 – egnite

egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

April 6, 2024

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to

Mortality Burden for Patients with Untreated Aortic Regurgitation

April 6, 2024

“This research underscores the poor outcomes for patients with moderate AR who exhibit cardiac damage, stressing the need to monitor for distinct characteristics in this population. These insights may also prompt a reassessment of our management strategies and suggest a shift in our approach to intensified follow-up for both moderate

egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Board

March 26, 2024

Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

March 19, 2024

Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking. egnite, a leading digital health company specializing in artificial intelligence solutions to advance cardiovascular care, stands at the forefront of innovation in the healthcare sector.

egnite, Inc. Unveils Research on Mitral Regurgitation at Transcatheter Cardiovascular Therapeutics Conference 2023

October 25, 2023

Led by Rahul Sharma MBBS, FRACP, and Colleagues, Findings Presented Today at the TCT Conference. Key Findings Demonstrate Patients with Moderate-to-Severe Mitral Regurgitation are 3 Times Less Likely to be Treated Than Patients with Severe Mitral Regurgitation Despite Similar Untreated Mortality…